Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Abbott Laboratories (ABT) had Consolidated Net Income/Loss of $1.78B for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$11.46B |
|
$1.78B |
|
$4.92B |
|
$6.54B |
|
$9.21B |
|
$2.25B |
|
$107.00M |
|
$2.36B |
|
$2.36B |
|
$1.78B |
|
$1.78B |
|
|
Consolidated Net Income/Loss |
$1.78B |
$1.78B |
|
$2.25B |
|
$3.04B |
|
1.74B |
|
1.75B |
|
$1.01 |
|
$1.01 |
|
| Balance Sheet Financials | |
$26.00B |
|
$11.82B |
|
$60.72B |
|
$86.71B |
|
$16.50B |
|
$9.90B |
|
$17.45B |
|
$33.94B |
|
$52.77B |
|
$23.21B |
|
$52.77B |
|
1.74B |
|
| Cash Flow Statement Financials | |
$9.57B |
|
$-2.42B |
|
$-6.31B |
|
$7.62B |
|
$8.52B |
|
$906.00M |
|
$664.00M |
|
$-4.12B |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.58 |
|
-- |
|
-- |
|
0.16 |
|
0.24 |
|
57.05% |
|
19.64% |
|
19.64% |
|
-- |
|
20.58% |
|
15.50% |
|
$7.39B |
|
-- |
|
-- |
|
-- |
|
0.13 |
|
0.76 |
|
1.45 |
|
62.28 |
|
3.37% |
|
7.65% |
|
2.05% |
|
2.83% |
|
$30.39 |
|
$4.23 |
|
$5.47 |
|